Most people take Xarelto for at least 3 months after a blood clot, but the full duration depends on what caused the clot and how likely it is to come back. Some people stay on it for 6 months, others for years, and some indefinitely. The single biggest factor in that decision is whether your clot had a clear, temporary trigger or appeared without an obvious cause.
The Two Treatment Phases
Xarelto treatment for a blood clot (whether in the leg or lungs) follows a specific dosing pattern. For the first 21 days, the dose is 15 mg taken twice daily with food. After that initial period, you switch to 20 mg once daily with food. This higher-frequency loading phase helps get the clot under control quickly, and the once-daily maintenance dose keeps it from growing or returning.
From there, treatment breaks into two broader windows. The initial treatment phase covers the first 3 to 6 months. At the end of that window, your doctor reassesses whether you need to continue into what’s called the extended treatment phase, which means staying on anticoagulation beyond 6 months with no set stop date.
Why the Cause of Your Clot Matters Most
Blood clots fall into two broad categories: provoked (meaning something identifiable triggered them) and unprovoked (meaning no obvious cause was found). This distinction drives nearly every decision about how long you stay on treatment.
Provoked clots with a major temporary trigger. If your clot happened after surgery, a major injury, or a long period of immobilization, the risk of it coming back after you stop treatment is low, typically less than 3% per year. In these cases, 3 months of Xarelto is often enough. Once the trigger is gone, your baseline clotting risk returns to normal.
Provoked clots with a minor or ongoing trigger. Clots linked to things like hospitalization for a medical illness, hormone therapy, or prolonged travel carry a moderate recurrence risk of 3% to 8% per year after stopping treatment. These situations often call for at least 6 months of treatment, sometimes longer depending on whether the trigger is still present.
Unprovoked clots. If no clear cause was found, your recurrence risk also falls in that 3% to 8% per year range. Current guidelines from the American Heart Association recommend continuing anticoagulation beyond the initial 3 to 6 months for people who had a first unprovoked clot, particularly if their bleeding risk is low. For many of these patients, treatment is extended indefinitely.
Who Needs Indefinite Treatment
Certain conditions make clot recurrence likely enough that stopping Xarelto becomes riskier than staying on it. People with inherited clotting disorders, such as protein C or protein S deficiency, or those who carry two copies of the Factor V Leiden mutation, are predisposed to forming new clots once anticoagulation stops. The same applies to people with antiphospholipid syndrome (lupus anticoagulant).
Active cancer is another common reason for open-ended treatment, since both the disease and its treatments raise clotting risk. If you’ve had two or more unprovoked clots, indefinite anticoagulation is generally recommended regardless of other factors. In all these scenarios, “indefinite” doesn’t mean the decision is never revisited. It means there’s no planned stop date, and your doctor will periodically weigh the ongoing benefit against your bleeding risk.
The Tradeoff: Clot Prevention vs. Bleeding Risk
Every month you stay on Xarelto reduces your chance of another clot, but it also carries a risk of serious bleeding. In studies of long-term use, the annual rate of major bleeding runs around 2.5% for people with normal kidney function. That risk climbs to roughly 4.5% per year for people with kidney disease. Age, history of stomach ulcers, and use of other medications that affect bleeding (like aspirin or anti-inflammatory drugs) also raise the risk.
This is the core calculation your doctor is making at each reassessment: does the chance of a new clot outweigh the chance of a serious bleed? For someone with an unprovoked clot and no bleeding risk factors, the answer usually favors continued treatment. For someone whose clot was triggered by a one-time surgery and who also has a history of GI bleeding, the math points toward stopping at 3 months.
Lower-Dose Option for Long-Term Prevention
If you’ve completed at least 6 months of full-dose treatment and your doctor recommends staying on anticoagulation, a lower 10 mg daily dose of Xarelto is an option for ongoing prevention. A large clinical trial (EINSTEIN CHOICE) compared this lower dose against daily aspirin in people who had finished their initial treatment course. The results were striking: recurrent clots occurred in just 1.2% of people on the 10 mg Xarelto dose compared to 4.4% of those on aspirin. Major bleeding rates were nearly identical between the two groups, at 0.4% and 0.3% respectively.
This lower dose gives a practical middle ground for people who need continued protection but want to minimize bleeding risk. Not everyone is a candidate for the step-down, so this is a conversation to have at your follow-up appointments.
What Happens When You Stop
Xarelto does not require tapering. When the time comes to stop, you simply take your last dose. There’s no need to gradually reduce the amount. However, stopping prematurely, before your prescribed course is finished, raises the risk of a new clot forming. The FDA’s prescribing information specifically warns that premature discontinuation of any oral anticoagulant increases the risk of clotting events.
If you need to stop Xarelto for a procedure or surgery, it should be discontinued at least 24 hours beforehand. In some cases your doctor may bridge you with a different anticoagulant during the gap. The key point is to never stop on your own. If side effects are bothering you or you’re unsure why you’re still taking it, that’s a conversation to have before skipping doses.
After stopping, there are no specific “rebound” symptoms to watch for, but the signs of a new clot are the same ones you may already know: swelling, warmth, or pain in one leg for a deep vein clot, or sudden shortness of breath and chest pain for a clot in the lungs.
Typical Timelines at a Glance
- Clot after major surgery or trauma: 3 months
- Clot with a minor or medical trigger: 3 to 6 months, possibly longer if the trigger persists
- First unprovoked clot, low bleeding risk: at least 6 months, often indefinite
- Recurrent unprovoked clots: indefinite
- Known clotting disorder or antiphospholipid syndrome: indefinite
- Active cancer: as long as cancer-related risk persists
These are starting points, not rigid rules. Your treatment length will be tailored to your specific combination of clot type, recurrence risk, bleeding risk, and personal preference. The 3-to-6-month mark is when the most important reassessment happens, so if that appointment isn’t already on your calendar, it should be.